Abstract
We report the case of a 16-year-old boy with cardiomyopathy induced by inappropriate sinus tachycardia (IST). The patient was resistant to treatment with conventional rate-decreasing medications. Therapy with the selective sinus node If current inhibitor ivabradine was started. After 3 months of ivabradine therapy, an improvement in ejection fraction and a successful decrease in heart rate were observed. No side effects occurred. We suggest that ivabradine, currently used to treat stable angina, could be considered as a second-line treatment in patients with symptomatic and refractory IST.
References
Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al (2003) CC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias―executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias). Circulation 108:1871–1909
Brady PA, Low PA, Shen WK (2005) Inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome, and overlapping syndromes. Pacing Clin Electrophysiol 28:1112–1121
Fox K (2005) Future perspectives of If inhibition in various cardiac conditions. Eur Heart J 7(Suppl H):H33–H36
Khan S, Hamid S, Rinaldi C (2009) Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker. Pacing Clin Electrophysiol 32:131–133
Khasnis A, Jongnarangsin K, Abela G, Veerareddy S, Reddy V, Thakur R (2005) Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol 28:710–721
Marrouche NF, Beheiry S, Tomassoni G, Cole C, Bash D, Dresing T et al (2002) Three-dimensional nonfluoroscopic mapping and ablation of inappropriate sinus tachycardia. Procedural strategies and long-term outcome. J Am Coll Cardiol 39:1046–1054
Schulze V, Steiner S, Hennersdorf M, Strauer BE (2008) Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology 110:206–208
Shen WK (2005) How to manage patients with inappropriate sinus tachycardia. Heart Rhythm 2:1015–1019
Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM (1997) Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 29:709–715
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885
Winum PF, Cayla G, Rubini M, Beck L, Messener-Pellenc P (2009) A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. PACE 32:942–944
Yusuf S, Camm AJ (2003) Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? J Cardiovasc Pharmacol Ther 8:89–105
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romeo, E., Grimaldi, N., Sarubbi, B. et al. A Pediatric Case of Cardiomyopathy Induced by Inappropriate Sinus Tachycardia: Efficacy of Ivabradine. Pediatr Cardiol 32, 842–845 (2011). https://doi.org/10.1007/s00246-011-9964-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-011-9964-1